CONTEXT: The care of patients with hypothalamic obesity is challenging. OBJECTIVE: To compare body composition, basal metabolic rate (BMR) and metabolic outcomes of adults, with lesional or genetic hypothalamic obesity, with obese patients suffering from primary obesity, once matched for body mass index (BMI). DESIGN AND PATIENTS: Adults with hypothalamic obesity of genetic origin (Prader Willi syndrome (PWS)) or acquired hypothalamic damage (HD), such as craniopharygioma, were compared with obese control candidates awaiting bariatric surgery (C), with a BMI between 35 and 65 kg m À 2 , and aged between 18 and 50 years. MAIN OUTCOME MEASURES: Body composition measured by whole-body dual-energy X-ray absorptiometry scanning, BMR using indirect calorimetry, hormonal and metabolic assessments. RESULTS: A total of 27 adults with a genetic diagnosis of PWS, 15 obese subjects with HD and 206 obese controls with similar BMI were studied. Compared with the control group, PWS patients had an increased percentage of fat mass (FM), and a decreased percentage of android FM. The BMR of PWS patients was significantly lower than controls and highly correlated with lean body mass in PWS and C patients. Body composition of HD was similar with those of obese patients. A trend toward an increased prevalence of diabetes in HD patients and of cytolysis in PWS was observed in comparison with primary obese patients. CONCLUSION: Genetic and lesional hypothalamic obesities have different consequences for phenotypic features such as body composition or BMR compared with primary obese patients. The mechanisms of adipose tissue development and metabolic complications may be different between genetic and lesional obesities.
INTRODUCTION
Obesity can be classified as primary or secondary. Primary obesity is the result of the interaction between a polygenic predisposition and behavioral and environmental factors (energy intake, physical activity), whereas secondary obesities because of functional or anatomical dysfunction of the hypothalamus can be either secondary to genetic anomalies or lesional damage (that is, hypothalamic obesity). 1 Hypothalamic obesity because of hypothalamic damage (HD) occurs in subjects previously healthy from an endocrine and nutritional perspective, for whom the disease profoundly alters hypothalamic function. Craniopharyngioma (CP) is the most common tumor affecting the hypothalamic-pituitary area, responsible for obesity in 50% of cases. [2] [3] [4] Other rare causes of HD include inflammatory disease, such as sarcoidosis and tuberculosis, head trauma, and radiation. Reductions in basal metabolic rate (BMR) and physical activity, impaired sensitivity to feeding-related signals, and hyperinsulinemia have all been suggested as major mechanisms of action for obesity development in adults with childhood onset CP. 5 In comparison with children and adolescents, features of the metabolic syndrome in adults with HD are limited, especially in adults with severe obesity. 6 Hypothalamic obesity can also be caused by genetic abnormalities, the most frequent being Prader Willi syndrome (PWS), when it is characterized by early weight gain and endocrine disorders. PWS is a complex genetic disease that occurs in 1/30 000 births 7 and arises from the lack of expression of genes on the paternally derived chromosome 15q11-q13. PWS is characterized by mild mental retardation, short stature, abnormal body composition, muscular hypotonia and distinctive behavioral features. Few studies have focused on the metabolic outcomes of obese PWS adults. 8, 9 In the clinical setting, the care of adults with hypothalamic obesity is challenging, whatever its origin. Understanding the pathophysiology of weight gain and its complications is incomplete, which makes clinical management difficult. A better knowledge of the clinical situations may help provide recommendations regarding their risk of morbidity and hence improve the medical care of these patients.
The aim of our study was to compare BMR, body composition and metabolic outcomes of two groups of adults with genetic and lesional hypothalamic obesity, and compare them with obese patients suffering from primary obesity, once matched for body mass index (BMI).
PATIENTS AND METHODS

Patients with hypothalamic obesity
Between July 2007 and September 2010, 172 patients were successively examined in the Nutrition Department of La Pitié Salpê triè re Hospital (Paris, France) for a diagnosis of hypothalamic obesity, suspected by the presence of obesity, feeding and pituitary disorders. Patients with hypothalamic obesity of genetic origin other than PWS were excluded because of the heterogeneity of their phenotypes. Ethical approval was obtained from the Research Ethics Committee of Hotel-Dieu Hospital (CPP Ile de France 1), Paris, and patients gave informed consent for the study. The inclusion criteria for this study were a BMI between 35 and 65 kg m À 2 (with a stable weight for the previous 6 months), age between 18 and 50 years, and having had an assessment of body composition and BMR during the same hospital stay or clinic visit. All our study clinical and biological investigations were performed on the same day for each patient.
Patients with PWS. Seventy-eight patients with abnormal methylation profile on chromosome 15 (36 deletion, 42 non-deletion including 7 uniparental disomy and 1 imprinting mutation) are under the care of our department. Twenty-seven of these patients fulfilled the inclusion criteria (18 deletion, 8 non-deletion and 1 imprinting mutation), 59% (16/27) were women, and their mean age was 25 ± 7.4 years. A 32-year-old woman was receiving growth hormone (GH) treatment since the age of 3 years, and five others had also been treated with GH in childhood or adolescence (mean duration of treatment ¼ 4.5 years (1-8 years)).
Patients with HD.
Fifteen patients with HD fulfilled the inclusion criteria: eight who had undergone surgery for CP, three with hypothalamic sarcoidosis and a current history of corticosteroid therapy, one hypothalamic meningioma, one hypothalamic tuberculosis, one astrocytoma and one with undetermined hypothalamic infiltrative disease without histological diagnosis.
The patients ranged from 4 to 49 years of age at diagnosis, and 4 of the 15 patients had developed their disease before 15 years of age.
A third (5/15) were women, and the median age of the patients was 36.6±14.2 years. The median follow-up duration after HD diagnosis was 12 years. Among the four patients who began to suffer from CP in childhood, a 27-year-old man was currently receiving GH treatment, and the others were treated during childhood or adolescence.
Obese control population (C)
Between July 2007 and September 2010, 300 patients who were candidates for bariatric surgery with a BMI between 35 and 65 kg m À 2 , aged between 18 and 50 years, were admitted to the Nutrition Department and assessed for BMR, body composition and metabolic outcomes. They were included in a study protocol approved by the Ethics Committee of Hotel Dieu Hospital, and signed informed written consent. Only those patients with complete and available nutritional and metabolic and hormonal assessments were included in the study. None of the patients had any hormone deficiency other than age-related menopause as assessed by a full hormonal evaluation, or any clinical characteristic suggesting hypothalamic obesity (diabetes insipidus, compulsive behavior including eating disorders, neurovegetative disorders). Systematic screening of MC4R mutation had been previously performed and patients with the mutation were excluded. In all, 206 patients fulfilled the criteria. Eightyfive percent (176/206) were women, and the median age of the women was 36.5 ± 8.4 years, whereas for the men it was 41.7 ± 7.9 years.
Body composition measurements
Body composition assessment was performed by the same investigator. Height was measured to the nearest 5 mm, without shoes, using a wallmounted stadiometer. Weight was measured to the nearest 0.1 kg using the TANITA BC420MA Bioelectrical Impedance (Tanita, Tokyo, Japan) as a weight scale and BMI was calculated as the weight in kilograms divided by the square of height in meters (kg m À 2 ). Body composition was estimated by whole-body dual-energy X-ray absorptiometry scanning (DXA) (Hologic Discovery W, software v12.6, 2; Hologic, Bedford, MA, USA), as previously described. 10 For each pixel, the equipment calculates weight, bone mineral content and fat mass (FM). Android FM was determined from DXA following the protocol utilized by Talebizadeh and Butler. 11 Indirect calorimetry was performed in all fasting subjects using a ventilated hood system (Deltatrac, Datex, France). The subject should not have smoked or ingested caffeine before assessment. BMR was calculated by an equation supplied by the manufacturer.
The predicted BMR was calculated using the Harris and Benedict Equation (pBMR1) and the Mifflin Saint Jeor Equation (pBMR2). 12 Blood metabolic profile and blood pressure Blood samples were taken after a 12-h overnight fast. Serum glycemia, insulinemia, HbA1C, triglycerides, and total, low and high-density lipoprotein cholesterol were analyzed in the laboratory at Pitié Salpé triè re Hospital. Systolic and diastolic blood pressures were measured after 10 min at rest and the lowest value was used.
Definitions
Persons with fasting blood glucose above or equal to 7.0 mmol l À 1 , or who were taking anti-diabetic medication were considered as having diabetes mellitus. 13 The Cardiovascular risk factors were defined by the European guidelines on cardiovascular prevention. 14 Arterial hypertension was considered present when measurement of brachial blood pressure exceeded 140 mm Hg (systolic) and/or 90 mm Hg (diastolic) on at least two different occasions, or if the patient was on antihypertensive medication.
Hypercholesterolemia was defined as total cholesterol above or equal to 5.7 mmol l À 1 , or the presence of statin treatment. Hypertriglyceridemia was defined as serum triglycerides above or equal to 1.7 mmol l À 1 , or as being prescribed fibrates. A low high-density lipoprotein was defined as high-density lipoprotein cholesterol below 1.03 mmol l À 1 in men and 1.29 mmol l À 1 in women. 15 We estimated insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR) index in patients without insulin therapy, using the formula: HOMA-IR ¼ insulinemia (mIU l À 1 ) Â fasting blood glucose (mmol l À 1 )/22.5. 16 Abnormal liver function tests or cytolysis was defined when liver enzymes (aspartateamino-transferase and/or alanine-amino-transferase) were at least 1.5 times higher than the upper limit of normal, which represents a predictive factor for steato-hepatitis. 17 
Statistical analysis
The three groups were comparable in terms of BMI, but age and sex ratios were different, and so results were adjusted for age and sex.
Results are means ± s.d. Contingency tables were performed for analysis of categorical data. Non-parametric Wilcoxon and w 2 tests (or Fisher's exact test for small samples size) were used for mean comparison of continuous data (bio-clinical parameters) or non-continuous data in the three different groups of patients. Statistical analysis was performed with JMP statistics software (SAS Institute Inc., Cary, NC, USA). All probabilities were two-tailed with the level of significance set at Po0.05.
RESULTS
Subject characteristics
The three groups, matched for BMI, differed in terms of gender and age despite a similar range. PWS patients were significantly younger than the other patients (25.7 ± 7.4 years vs 36.6 ± 14.2 in HD and 37.2 ± 8.5 in C patients). The prevalence of women was higher in C group. For these reasons, all the analyses were adjusted for age and separated for gender for body composition analysis. PWS patients were also significantly shorter (151.3 ± 10.9 cm) than both HD (168.0±9.9 cm) and obese C patients (166.1±8.1 cm).
Hormonal insufficiencies are reported in Table 1 . Gonadotropin insufficiency was present in 14/15 HD patients (93%), and 22/27 PWS patients (81%) with current replacement therapy in most cases. The prevalence of GH insufficiency was similar between groups (48%) and the patients were rarely receiving GH in adulthood (one patient of each group). Thyreotrope insufficiency was more prevalent in HD group (12/15) than PWS (4/27), and was prescribed in all cases. Corticotrope insufficiency was frequent in HD patients (87%) and always treated, whereas only two PWS patients displayed incomplete corticotrope insufficiency.
Body composition and BMR As expected, body composition differed significantly between men and women, and therefore our results are presented by gender. These results were similar when the patients with currently substituted GH insufficiency were excluded.
In men (Table 2 ): in the PWS group, the relative total FM and FM index (FM index ¼ FM height À 2 ) were significantly higher than in C and HD groups. The percentage of android FM was significantly lower in PWS patients than C and HD patients. Lean body mass (LBM) (in % and kg) was lower in PWS group than in the other groups.
The BMR was significantly lower in PWS than C men, but this difference in BMR did not reach statistical significance between PWS and HD patients. Adjusted for LBM, the BMR was similar between groups. Body composition and BMR were not different between C and HD patients.
In women (Table 3) : PWS women had a higher relative FM than C patients, and a lower android FM than both C and HD patients as reported in men. In contrast, LBM (in % and kg) was lower in the PWS group than C and HD patients. Only a trend toward a lower BMR in PWS women in comparison with the other groups was observed. Body composition and BMR were not different between C and HD patients.
In women and men, BMR was significantly correlated with LBM in PWS (r 2 ¼ 0.75, Po0.0001) and C patients (r 2 ¼ 0.5, Po0.0001) but not in HD patients.
To take into account the younger age of the PWS cohort, PWS subjects were compared with a subgroup of controls matched for age, sex and BMI (Supplementary Table 1 ). Similar results were observed for both BMR and body composition. Gonadotropin insufficiency was defined as replacement therapy (testosterone, estrogen and progestative), or testosteronemia in meno3 ng ml
and estradiolemia in womeno30 pg ml
, without increasing follicle stimulating hormone (FSH) or luteinizing hormone (LH) levels; somatotrope insufficiency as replacement therapy during childhood or adulthood (by growth hormone), or low plasmatic insulin like growth factor 1 (IGF1) according to the standards of the laboratory according to the age; thyreotrope insufficiency as replacement therapy (L-thyroxin), or free T4 o10 pmol l À 1 ; corticotrope insufficiency as replacement therapy (hydrocortisone), or free cortisol at 0800 hours o30 ng ml À 1 , or abnormal response to Synacthen test (that is, free cortisolo210 ng ml À 1 ). Different superscripts represent the number of subjects with hormonal data when it differs from the number of patients involved in the study: a n ¼ 20; 
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Metabolic outcomes in hypothalamic obesities
Metabolic outcomes are presented in the Table 4 . A trend toward a higher prevalence of diabetes in HD patients was observed (46.7% vs 22.2% and 24.3% in PWS and C patients, respectively, P ¼ 0.14). Two of the three patients with sarcoidosis were also diabetic and had been treated with corticosteroids. Other metabolic features were similar in both hypothalamic obesities and in the control obese groups. The prevalence of hypertriglyceridemia, low high-density lipoprotein and high blood pressure were similar between groups. Hypercholesterolemia was diagnosed in only 1 HD patient (6%), 4 of the 27 PWS (15%) and 54 (25%) of the 206 controls. An increased prevalence of abnormal liver function tests was observed in PWS patients but the difference did not reach significance. In patients without insulin therapy, fasting insulinemia (19.3 ± 23.7 IU l À 1 in PWS patients, 15.9 ± 11.3 in HD patients and 18.1±10.8 in C patients), the HOMA-IR (3.7±4, 3.9±2.2 and 3.5 ± 2.2 in PWS, HD and C patients) were similar in the three groups, after adjustment for age.
To take into account the younger age of the PWS cohort, PWS subjects were compared with a subgroup of controls matched for age, sex and BMI (Supplementary Table 1 ). We found similar results regarding the prevalence of diabetes, hypertension, dyslipidemia and cytolysis. However, fasting glycemia, and HOMA-IR were lower in PWS group (Supplementary Table 1 ).
DISCUSSION
Hypothalamic obesity results either from a genetic or anatomical cause. The clinical history of the obesity differs, with an early and progressive onset for PWS, and a later and sudden onset for HD. The determinants involved in the development of obesity in both cases are not well known. A better understanding of the metabolic complications and its determinants may be important in improving the challenging clinical management of these patients. In this context, we have compared phenotypic features such as body composition, BMR and metabolic outcomes for both etiologies, in severely obese adult patients.
In agreement with various other studies in both children and adults, we observed a reduced LBM, an increased total body FM, and reduced percentage of troncular adipose tissue in PWS patients in comparison with patients with primary obesity matched for BMI, despite the younger age of this group. 11, [18] [19] [20] [21] [22] [23] [24] The mechanisms of reduced LBM in PWS patients are not fully understood. GH deficiency is probably not the only cause, because GH treatment completely normalizes length but does not normalize body composition; muscle weakness and motors problems during all-life may also contribute to the reduced LBM. 25 Hypotonia and reduced LBM could represent features of specific muscular abnormalities whose molecular mechanisms are currently unknown.
As previously reported, the excess of FM was more pronounced in men than women in our study. 21 The lack of gonadotropins and low testosterone levels may be associated with lower lean mass growth and lower subcutaneous fat loss than usually seen in teenage boys. 21 Sode-Carlsen et al. 8 did not report significant differences between hypogonadal and eugonadal men regarding their body composition measurements, nor differences between men with or without testosterone treatment except for a tendency toward a higher thigh muscle/fat ratio in those receiving testosterone. However, Eiholzer et al. 26 reported virilization and normalization of muscle mass of PWS boys receiving a human chorionic-gonadotrophin substitution in the peripubertal period without detrimental effects on behavior. 27 In our study, hormonal substitution was lacking in many PWS men (1/3 of adults were currently being treated), as it has been associated with behavioral disorders, and therefore restricted social integration, which is clearly a priority in their management into adulthood. 28 Theodoro et al. 21 hypothetized that PWS men may be more efficient at fat deposition than normal individuals. Larger studies are needed in order to establish the need for sex-steroid replacement to improve muscle mass, and its effects on behavior. Furthermore, the mechanism of the reduction in visceral adiposity in PWS is still unclear. It could be related to childhood-onset GH deficiency, defects in hypothalamo-pituitary-adrenal axis activity, or novel hypothalamic or genetic influences on the control of body fat distribution.
Body composition was not different in HD patients compared with C patients, as previously reported in adolescent CP. 29 In patients who developed the disease during childhood, hyperinsulinemia or adequate GH substitution may have been sufficient for growth and LBM development. 30, 31 In the case of diseases beginning in adulthood (2/3 of patients), hormonal deficiencies may have not changed the relative excess of adipose tissue observed in primary obesity, in agreement with the study of Muller, 32 where pituitary disorders did not influence weight gain after childhood CP. Hence, HD patients have in many ways suddenly developed a model of primary obesity.
In addition, the difference in fat distribution between PWS patients and those acquiring HD is surprising and may relate to the time of onset and the subsequent treatment. However, it is not excluded that FM development is driven by different molecular mechanisms.
In this cohort of severely obese PWS subjects, BMR was significantly decreased in men and with a trend for women but when adjusted for LBM, this difference did not remain significant. In addition, the close relationship between BMR and LBM suggests the major role of LBM as a determinant of BMR, as has been previously described. 20, 22, 33, 34 Therefore, although it may be clinically challenging in these patients already characterized by hypotonia, any measure shown to increase LBM should be a priority in their clinical management. 35 In contrast, BMR was not correlated with LBM in HD patients, suggesting the complex involvement of hypothalamic factors and LBM in determining BMR. Few studies exist on BMR in HD patients Only determined in non-diabetic subjects and in diabetic subjects without insulin treatment.
Hypothalamic obesities outcomes in adults C Lloret-Linares et al and their designs were different from our study, making comparison difficult. 5, 29 Holmer et al. 5 reported a significantly higher BMR in obese CP patients than in non-obese control subjects, but lower BMR after adjustment for sex and total body weight. Adjustment for LBM was lacking, and may explain any differences with our study. Kim et al. 29 observed a BMR decreased by 17% despite similar fat-free mass in 11 obese CP adolescents compared with obese controls. Differences in BMR between C and HD patients may be higher during adolescence, when weight is still increasing, and may explain the difference with our study, where all patients had a stable weight for the previous 6 months. However, as in our study, Kim et al. 29 did not observe any correlation between BMR and fat-free mass. Hence, BMR in HD patient is difficult to predict without individual assessment. Systematic and repeated measures may be useful to individualize management.
In patients with severe obesity, the prevalence of most metabolic complications was similar between groups. Despite a higher FM, metabolic outcomes of obese PWS patients were not significantly different than an age, sex and BMI-matched control population, except for a decrease in insulin resistance, which can be explained by the reduced percentage of android FM. In addition, an excess subcutaneous tissue may limit the occurrence of most metabolic complications via an increased adiponectin, and lower inflammation. 8, 36, 37 It has yet been reported than PWS patients (mean age: 36.2 years, mean BMI: 32.2 kg m À 2 ) display lower hypertension and diabetes in adulthood than patients with primary obesity matched on BMI. 8, 38, 39 Moreover, in a cohort of 46 PWS patients with a mean BMI of 27.2 kg m À 2 and a mean age of 28 years, 34.7% patients had dyslipidemia and 15.2% were diabetic. 8 Hence, the higher the BMI, the higher the metabolic risk, despite reduced android FM. Therefore, the prevention of obesity onset remains an important role of PWS treatment. Actually, in this population, there will still be an absolute increased prevalence of metabolic disorders, such as type 2 diabetes mellitus and hypertension, despite the relatively less severe visceral adiposity. Further studies are needed to compare metabolic outcomes in PWS patients with control patients matched on visceral FM and age, and to assess if the quantitative changes observed in FM are associated with qualitative abnormalities of adipose tissue (adipocyte size, vascularization, inflammation and fibrosis).
It should be noted that almost 50% of patients in the HD group are diabetic. A decreased insulin sensitivity in childhood could predict this high prevalence. 6, 40, 41 However, the HOMA was similar among the three groups. The patients for whom the HOMA was performed may be those with the lower insulin resistance, in contrast with the others who are already diabetic and treated with insulin. Moreover, a lower occurrence of diabetes was reported in the literature. Lee and Korner 42 observed only one case of diabetes in a cohort of 66 patients, in whom CP was diagnosed at a mean age of 8 years and after a mean follow-up of 7.2 years. In addition, Crowley et al. 43 reported a prevalence of diabetes of 11.5% in a population of moderate obesity (mean BMI: 31.8 kg m À 2 ), but glycemia data were not available for all patients, especially those who died before the study (21 of the 70 patients). Thus, this prevalence may increase in HD adults, as observed in our study. However, the high prevalence may also be explained by the cases of hypothalamic sarcoidosis included in our cohort. Indeed two of these three patients were diabetic, and corticosteroid use may explain this diabetic excess. Thus, in the case of hypothalamic sarcoidosis, an alternative treatment to corticosteroids should be discussed. 44 The prevalence of hypertension was similar between patients groups, and similar to that observed in the population suffering from severe obesity and awaiting bariatric surgery. 45 It therefore appears that hypothalamic obesity does not modify the risk of hypertension.
Our paper has several limits, some of which have been discussed previously. It is a retrospective study, with a limited number of subjects but it focused on body composition and the metabolic outcomes of patients with a rare disease and whose care is frequently challenging in adulthood. In addition, control patients were not matched with PWS and HD populations on age, since themselves differed in terms of age. Indeed, to match control patients on age and BMI, two control populations would have been necessary. Hence, we decided to include a larger control population and to adjust the results on age, rather than to reduce the sample size of the control population. Actually, the differences in metabolic outcomes in PWS may be related to the differences in age but these remain significant after adjustment. In addition, it has yet been reported that visceral adiposity and insulin resistance are decreased in PWS in comparison with obese patients matched on BMI and age 21, 24 Furthermore, the study was performed at a late stage of the disease, when obesity determinants are not necessarily representative of the dynamic phase of weight gain. Finally, some complementary information is missing, such as physical activity and eating behavior.
In conclusion, the two hypothalamic obesities studied here, of genetic or lesional origins, have different consequences for body composition and BMR, suggesting that development of adipose tissue is not driven by the same mechanisms. With a similar body composition, HD patients display such a high risk of metabolic complications than patients with primary obesity. This metabolic risk adds to the increased risk for morbidity and mortality of HD patients, caused by the occurrence of cardiorespiratory events, the local complications after the treatment of hypothalamic disease and their recurrence. 43 Conversely, it is well known that PWS patients have a much more higher estimated mortality rate than the general and obese population, but their excess of FM seems less likely to develop metabolic complications than HD patients and subjects with primary obesity, as their visceral FM is reduced. 46, 47 Cardiorespiratory diseases, infections and sudden death are contributing to the higher mortality both in children and adults with PWS. 48, 49 In future, it would be interesting to prospectively compare the kinetics of the early phases of weight gain, when hopefully improved care for each of the different etiologies of hypothalamic disorders, may result in a reduction in obesity and its complications.
